FDA Aims To Clarify Human Cell/Tissue Regulation With Upcoming Meeting, Guidance Documents
This article was originally published in The Gray Sheet
Executive Summary
FDA announced an April hearing to discuss four open draft guidance documents clarifying the regulation of human cells, tissues, or cellular or tissue-based products.
You may also be interested in...
FDA Considers New Regulatory Pathways For Some Cellular Products
The US agency is re-evaluating its criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs. A 2014 guidance on cord blood products could serve a template, industry suggests.
Devices Addressed In US FDA's New Regenerative Medicine Framework
The framework includes two draft guidance documents and two final guidances. One of the drafts, which focuses on the regulation of devices used with regenerative medicine, implements a provision of the 21st Century Cures Act and strongly suggests that most of these products will be regulated via class II.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”